Drug Information

Drug General Information
Drug ID
D0F1CE
Former ID
DNCL001817
Drug Name
LCQ908
Drug Type
Small molecular drug
Indication Familial chylomicronemia syndrome; HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:J10, J11, B17.1, B18.2] Phase 3 [523768], [542776]
Company
Novartis
Structure
Download
2D MOL

3D MOL
Formula
C25H24F3N3O2
InChI
InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)/t16-,17-
InChIKey
GXALXAKNHIROPE-QAQDUYKDSA-N
PubChem Compound ID
53387035
Target and Pathway
Target(s) Diglyceride acyltransferase Target Info Modulator [531007]
BioCyc Pathway Triacylglycerol biosynthesis
KEGG Pathway Glycerolipid metabolism
Retinol metabolism
Metabolic pathways
Fat digestion and absorption
PathWhiz Pathway Retinol Metabolism
Reactome Acyl chain remodeling of DAG and TAG
Triglyceride Biosynthesis
WikiPathways Vitamin A and Carotenoid Metabolism
Statin Pathway
Triacylglyceride Synthesis
Glycerophospholipid biosynthesis
Fatty acid, triacylglycerol, and ketone body metabolism
References
Ref 523768ClinicalTrials.gov (NCT01514461) A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. U.S. National Institutes of Health.
Ref 542776(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7830).
Ref 531007DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.